title: Cutaneous dermatomyositis in the era of biologicals.
abstract: Dermatomyositis (DM) is a systemic inflammatory condition characterized by cutaneous and muscle findings, in addition to potential involvement of other organ systems. A distinct subtype of DM exists that is categorized by cutaneous findings with absent or minimal muscle involvement, referred to as clinically amyopathic dermatomyositis or dermatomyositis sine myositis. A variety of topical, immunosuppressive, and immunomodulatory therapies have been utilized to treat cutaneous DM. The advent of biological agents including tumor necrosis factor-α antagonists, intravenous immunoglobulin, rituximab, and others has allowed for the use of these agents with varying degrees of success for the treatment of cutaneous DM.
authors.affiliation: Brigham and Women's Hospital, Department of Dermatology, 221 Longwood Ave, Boston, MA, 02115, USA.
authors.forename: Natalie A
authors.initials: NA
authors.lastname: Wright
authors.affiliation: Brigham and Women's Hospital, Department of Dermatology, 221 Longwood Ave, Boston, MA, 02115, USA.
authors.forename: Ruth Ann
authors.initials: RA
authors.lastname: Vleugels
authors.affiliation: Department of Medicine, Division of Dermatology, University of Louisville, 3810 Springhurst Blvd, Louisville, KY, 40241, USA. jeffreycallen01@gmail.com.
authors.forename: Jeffrey P
authors.initials: JP
authors.lastname: Callen
mesh_terms: D001688:Biological Products / Q000494:pharmacology / Q000627:therapeutic use*; D003882:Dermatomyositis / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology / Q000627:therapeutic use; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use; D000069283:Rituximab / Q000494:pharmacology / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D001688:Biological Products; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab
keywords: Amyopathic dermatomyositis; Biologicals; Cutaneous dermatomyositis; Intravenous immunoglobulin; Rituximab; TNF-α antagonists